SEC Form 4 · accession 0001209191-15-044094

ALDER BIOPHARMACEUTICALS INC · ALDR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 14, 2015

Accepted (ET)

May 18, 2015 · 8:51 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001423824

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	May 14, 2015	M	18,181	$0.33	A	42,625	D
Common Stock^F1	May 14, 2015	S	18,181	$35.0408	D	24,444	D
Common Stock^F2	May 18, 2015	S	20,000	$39.9709	D	4,444	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$0.33	May 14, 2015	M	18,181	D	—	Nov 14, 2015	Common Stock	18,181	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.77 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
F3The option was fully vested.